Evidence map›Paper›PMID 41333182›Full record

ArticleAdvances in radiation oncology2025

Risk Factors of Cardiotoxicity After Breast Cancer Radiation Therapy.

Felicia B Guo, Hyunsoo Joshua No, Natalie J Park, Santino Butler, Scott Jackson, June-Wha Rhee, Daniel Eugene Clark, Carol Marquez, Kathleen Claire Horst, Michael Sargent Binkley

Abstract read
In one paragraph

Article in Advances in radiation oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Felicia B GuoUniversity of Rochester School of Medicine & Dentistry, Rochester, New York.
Hyunsoo Joshua NoDepartment of Radiation Oncology, Southern California Permanente Group, Pasadena, California.
Natalie J ParkDepartment of Radiation Oncology, Stanford Medicine, Palo Alto, California.
Santino ButlerDepartment of Radiation Oncology, Stanford Medicine, Palo Alto, California.
Scott JacksonDepartment of Radiation Oncology, Stanford Medicine, Palo Alto, California.
June-Wha RheeDepartment of Medicine, Division of Cardiology, City of Hope Comprehensive Cancer Center, Duarte, California.
Daniel Eugene ClarkDepartment of Medicine, Division of Cardiology, Stanford University, Palo Alto, California.
Carol MarquezDepartment of Radiation Oncology, Stanford Medicine, Palo Alto, California.
Kathleen Claire HorstDepartment of Radiation Oncology, Stanford Medicine, Palo Alto, California.
Michael Sargent BinkleyDepartment of Radiation Oncology, Stanford Medicine, Palo Alto, California.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Purpose: Concern for cardiotoxicity after the treatment of breast cancer necessitates a better understanding of factors that may increase the risk of significant (grade ≥3) cardiac events. We investigated clinical factors, coronary artery calcium (CAC), and radiation therapy dose to cardiac structures as predictive post-radiation therapy cardiotoxicity risk factors. Methods and Materials: We retrospectively analyzed a cohort of serial patients treated with neoadjuvant chemotherapy for stage I to III breast cancer from 2005 through 2014. We measured the incidence of cardiac events after treatment, adjusting for the competing risk of death. Results: We identified 174 patients with a median follow-up of 117 months and a median age of 47 years. The 10-year incidence of grade ≥3 cardiac events was 8.5% (95% CI, 4.7%-13.6%) with 13 events observed. 78.9% of the 166 patients with available imaging had no measurable CAC. Patients with nodal positivity (N Conclusions: In a cohort of patients with breast cancer with low CAC burden and overall low doses of radiation, we observed low rates of cardiotoxicity. However, our findings identify patients with nodal positive disease as a particularly high-risk group, suggesting that close follow-up and optimization of therapies for this subgroup is needed.

Identifiers

PMID41333182
PMCPMC12666710

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.